Xcout IntelPhoremost
PhoreMost Ltd is a Cambridge, United Kingdom-based biotechnology and drug discovery company dedicated to turning scientific breakthroughs into life-changing cancer therapies.
Subscribe to see Phoremost’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Phoremost at a glance
Phoremost is a biotechnology company headquartered in United Kingdom, founded in 2014. Its most recent funding round, Series B, raised $12M in September 2024. Xcout tracks 10 named people at Phoremost, including Neil Torbett (CEO).
Phoremost leadership
- Neil TorbettCEO
- Andrew MunceyCFO
- Barbara DuncanChair / NED
- Christian DillonCSO
- Gabriel FoxCMO
- Chris TorranceFounder / NED
4 more named people on record for Phoremost, with roles, board committees and tenure — see the full roster →
Phoremost funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $12M | 5 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Phoremost competitors
A few of Phoremost's closest competitors — see the full list of competitors and alternatives →
Crescendo Biologics Ltd., associated with originator organization Crescendo Bioscience LLC, is a biotechnology company headquartered in Cambridge, UK. The firm develops targeted drug pipelines, particularly focusing on oncology and PSMA-positive castration-resistant prostatic cancer treatments.
Metaphore Biotechnologies, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, operating as part of Flagship Pioneering. The company focuses on therapeutic design, leveraging AI and machine learning technologies for drug discovery and development.
Mission Therapeutics is a drug discovery and development company recognized as a global leader in targeting deubiquitylating enzymes. Founded in 2011, the firm is based at the Babraham Research Campus in Cambridge, United Kingdom.
Dark Blue Therapeutics is an innovative drug discovery biotechnology company based in Oxford, United Kingdom, focused on early oncology research before being acquired by Amgen.
Sareum Holdings plc operates as a specialized pharmaceutical company, primarily focused on discovering and advancing innovative therapeutic compounds for treating both cancer and autoimmune conditions. The firm develops small-molecule drugs, utilizing its proprietary Sareum Kinase Inhibitor Library as its core drug discovery platform. Its development portfolio currently features programs targeting Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. Sareum has also forged strategic partnerships with the Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. Founded in 2003, the company is headquartered in Cambridge, United Kingdom.
Get Phoremost's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Phoremost in Xcout Intel
- 10 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access